[Plasma concentration of peplomycin following intravenous infusion and subcutaneous infusion in patients with malignancies].
Five mg of peplomycin was administered continuously for 24 hours by intravenous or subcutaneous infusion. Subcutaneous administration of peplomycin was performed done with the use of an SP-5 microinfusion pump made by the in Nipro Company. The plasma concentration after intravenous infusion was 0.0106 +/- 0.039 microgram/ml, while that after subcutaneous infusion was 0.131 +/- 0.037 microgram/ml. There was no statistical significance between the differences observed for intravenous and subcutaneous infusion.
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000097:blood*; D001761:Bleomycin / Q000008:administration & dosage / Q000097:blood*; D004938:Esophageal Neoplasms / Q000097:blood; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008223:Lymphoma / Q000097:blood; D008297:Male; D009369:Neoplasms / Q000097:blood*; D017663:Peplomycin; D011471:Prostatic Neoplasms / Q000097:blood
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; D017663:Peplomycin